Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × NSCLC × sugemalimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1 Neoplasm, Residual 1 NSCLC 1 Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Drug Therapy 8 osimertinib 7 Pemetrexed 7 Radiotherapy 6 anlotinib 5 Carboplatin 5 Radiosurgery 4 Gefitinib 4 Docetaxel 4 tislelizumab 3 pembrolizumab 3 icotinib 3 aflutinib 3 Vinorelbine 3 Gemcitabine 3 Erlotinib Hydrochloride 3 Cisplatin 3 toripalimab 2 dacomitinib 2 apatinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Paclitaxel 2 Immune Checkpoint Inhibitors 2 Chemotherapy, Adjuvant 2 Chemoradiotherapy 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07247227 2025-11-25

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

Peking Union Medical College

Phase NA Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡